The shadow of generic challenges has consistently loomed over copyright’s blockbuster drug, Sildenafil, sparking questions about the future of connected drug ventures. While early years saw impressive profits, the intellectual property lapse has opened the path for cheaper copies, possibly lowering earnings and posing a genuine danger for stakeho